Acta Haematologica最新文献_第8页

Prognostic Factors for Chronic Thrombocytopenia in Systemic Lupus Erythematosus with Immune Thrombocytopenia. 系统性红斑狼疮伴免疫性血小板减少症患者慢性血小板减少症的预后因素。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2024-07-29 DOI: 10.1159/000540192

Soo Min Ahn, Eun-Ji Choi, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong

{"title":"Prognostic Factors for Chronic Thrombocytopenia in Systemic Lupus Erythematosus with Immune Thrombocytopenia.","authors":"Soo Min Ahn, Eun-Ji Choi, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong","doi":"10.1159/000540192","DOIUrl":"10.1159/000540192","url":null,"abstract":"Introduction: We aimed to identify the clinical characteristics and risk factors for chronic immune thrombocytopenia (ITP) in patients with systemic lupus erythematosus (SLE).Methods: We retrospectively reviewed patients diagnosed with SLE-associated ITP between January 2000 and December 2021. Patient characteristics were analyzed according to the progression of chronic thrombocytopenia. No response was defined as a platelet count <30 × 109/L or less than double the baseline count after treatment. Factors associated with chronic ITP were evaluated by logistic regression analysis.Results: Among the 121 patients with SLE-associated ITP, 27 progressed to chronic ITP lasting more than 1 year after initial diagnosis. The median initial platelet count was significantly lower in patients with chronic thrombocytopenia than in those without the disease (16 vs. 51 × 109/L). Patients who did not achieve a response within 1 month of treatment exhibited a high probability of progressing to chronic ITP (55.6 vs. 22.3%, p < 0.001). Multivariable analysis revealed that severe thrombocytopenia at baseline (<20 × 109/L) (adjusted odds ratio [aOR] = 13.628, 95% confidence interval [CI] = 3.976-46.791) and no response within 1 month (aOR = 9.171, 95% CI = 2.776-30.298) were significantly associated with the risk of progression to chronic ITP in patients with SLE. Approximately one-quarter of the patients with SLE-associated ITP progressed to chronic ITP.Conclusion: Severe thrombocytopenia and failure to achieve a response within 1 month were risk factors for the development of chronic ITP in those patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"280-288"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141791634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study. 在治疗复发/难治性B细胞前体急性淋巴细胞白血病时，将Blinatumomab的用药时间缩短至14天具有相同的疗效和安全性：一项回顾性单中心研究。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.1159/000542060

Jinyu Kong, Wenjing Miao, Jialing Lu, Yin Liu, Xin Kong, Huiying Qiu, Baoquan Song

{"title":"Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.","authors":"Jinyu Kong, Wenjing Miao, Jialing Lu, Yin Liu, Xin Kong, Huiying Qiu, Baoquan Song","doi":"10.1159/000542060","DOIUrl":"10.1159/000542060","url":null,"abstract":"Introduction: Treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) remains a significant clinical challenge. Many new strategies are changing the treatment landscape of r/r BCP-ALL in recent years. Blinatumomab has improved outcomes in r/r BCP-ALL, though high treatment costs and extended hospital stays are significant concerns. We considered that shortening the duration of blinatumomab administration during induction therapy might solve these problems.Methods: We retrospectively analyzed 19 patients with r/r BCP-ALL treated with different durations of blinatumomab, where 10 patients received blinatumomab for 14 days (Bli 14D group) and 9 received it for a longer duration (LT group, 21-28 days).Results: The overall response rate (ORR) was 63.2% (12/19) of patients in total, and the ORRs in 14D and LT groups were almost the same (60% and 66.6%, respectively). The median overall survival was not reached in either groups. The median event-free survival time was 4.1 months in LT group and not reached in D14 group. The most common adverse events were consistent with previous reports, including cytokine release syndrome, neurologic toxicity, and hematological toxicity.Conclusion: A 14-day blinatumomab administration may be a promising and well-tolerated regimen in r/r BCP-ALL, offering the same ORR and survival rates.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"437-442"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review. 对急性白血病临床可操作的机器学习和人工智能算法：系统的叙述回顾。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2025-07-24 DOI: 10.1159/000547532

Jean M G Sabile, Ping Zhang, Anil V Parwani, Boris Chobrutsiky, Arpita P Gandhi, Andrew Srisuwananukorn

{"title":"Toward Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review.","authors":"Jean M G Sabile, Ping Zhang, Anil V Parwani, Boris Chobrutsiky, Arpita P Gandhi, Andrew Srisuwananukorn","doi":"10.1159/000547532","DOIUrl":"10.1159/000547532","url":null,"abstract":"Introduction: Acute myeloid leukemia (AML) is a heterogenous hematologic malignancy that maintains high relapse rates and poor survival despite ongoing treatment advances. There is critically unmet need for consistently providing long-term survival with minimal treatment toxicity for AML patients. Advances in artificial intelligence/machine learning (AI/ML) offer new approaches to addressing clinical challenges in AML.Methods: In this systematic narrative review, 426 publications focusing on the intersection of AML and AI/ML between January 1, 2010, and July 30, 2024, are reviewed.Results: The evolution of AI/ML tools over time is described from a clinically relevant perspective with a distinction between early epochs of AI/ML versus more contemporary algorithms, such as generative adversarial networks and transformer-based algorithms. This review highlights the utilization of contemporary AI/ML algorithms via addressing diagnostic challenges, molecular risk stratification problems, and clinical outcome prediction in the context of AML.Conclusion: Overall, AI/ML represents a promising new frontier in approaching clinical problems in AML, though there are still opportunities for utilization, particularly in the setting of allogeneic stem cell transplantation.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"583-599"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prelims. 预备考试。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2025-09-19 DOI: 10.1159/000548410

引用次数: 0

Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis. 在骨髓纤维化和贫血或血小板减少症患者中实际使用 Ruxolitinib。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2024-10-21 DOI: 10.1159/000541549

Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein

{"title":"Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis.","authors":"Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein","doi":"10.1159/000541549","DOIUrl":"10.1159/000541549","url":null,"abstract":"Introduction: Ruxolitinib is approved for treatment of myelofibrosis. We evaluated ruxolitinib in patients with anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelet count ≤100 × 109/L) at diagnosis.Methods: This was a retrospective, secondary analysis of a Cardinal Health Oncology Provider Extended Network medical chart review of adults with myelofibrosis diagnosed between 2012 and 2016 who received first-line ruxolitinib.Results: 176 patients received first-line ruxolitinib and were included in this analysis. At diagnosis, 120 patients had hemoglobin concentrations <10 g/dL and 59 had a platelet count ≤100 × 109/L. Most patients (95%) with thrombocytopenia also had anemia. Median time of observation after diagnosis was 21.4 months. Among patients with anemia or thrombocytopenia, ruxolitinib dose at end of study was ≥10 mg twice daily (bid) in 88.3% and 83.1%, respectively. Ruxolitinib treatment was ongoing in 76.1% of patients overall and was rarely discontinued for anemia or thrombocytopenia (n = 2 total, 1.1%). Per the treating physician, 79.7% of patients had improved symptoms and 62.7% improved spleen size.Conclusion: Most patients with myelofibrosis and anemia or thrombocytopenia at diagnosis tolerated and maintained a ruxolitinib dose ≥10 mg bid for nearly 2 years, resulting in clinical benefit. This real-world evidence supports observations from prospective clinical trials of ruxolitinib in myelofibrosis.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"408-418"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in Hemophilia Management: Revolutionizing Patient Care and Future Directions. 血友病管理中的人工智能：革命性的患者护理和未来方向。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2025-06-24 DOI: 10.1159/000546954

Sarina Levy-Mendelovich, Benjamin S Glicksberg, Shelly Soffer, Moran Gendler, Orly Efros, Eyal Klang

{"title":"Artificial Intelligence in Hemophilia Management: Revolutionizing Patient Care and Future Directions.","authors":"Sarina Levy-Mendelovich, Benjamin S Glicksberg, Shelly Soffer, Moran Gendler, Orly Efros, Eyal Klang","doi":"10.1159/000546954","DOIUrl":"10.1159/000546954","url":null,"abstract":"Background: Recent advancements in artificial intelligence (AI) hold significant promise for transforming hemophilia care. Summary: This review explores the impact of AI on critical aspects of hemophilia management, including bleeding risk prediction, biomarker identification, personalized treatment strategies, and patient education. Key Messages: We discuss the application of machine learning models in predicting bleeding risks among children with hemophilia engaging in physical activities, the use of AI in analyzing factor VIII protein structures to determine disease severity, and the development of AI-powered chatbots and digital platforms for patient education and self-management, particularly in resource-limited settings. Furthermore, we address the challenges inherent in implementing AI technologies in clinical practice, such as data privacy concerns, model interpretability, and the need for robust validation. By highlighting current advancements and future directions, we underscore the potential of AI to enhance personalized care and improve outcomes for individuals with hemophilia. .","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"546-555"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[r/r DLBCL: Heilungschance mit Axi-Cel]. [r/r DLBCL：轴细胞治疗的机会]。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2025-09-16 DOI: 10.1159/000548308

引用次数: 0

[PharmaNews]. [PharmaNews]。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2025-04-29 DOI: 10.1159/000546202

引用次数: 0

Biologic and Clinical Characteristics of Isochromosome der(17)(q10)t(15;17) in Acute Promyelocytic Leukemia. 急性早幼粒细胞白血病中同源染色体 der(17)(q10)t(15;17) 的生物学和临床特征。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2024-05-31 DOI: 10.1159/000539159

Yuchen Liu, Yi Ning, Gabriel Ghiaur, Ashkan Emadi

引用次数: 0

Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. 因子 VIII 水平和 ISTH DIC 评分并不能区分 DIC 和肝病凝血病。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-01-01 Epub Date: 2024-07-16 DOI: 10.1159/000540239

Cecily Allen, Marina Heskel, Ayesha Butt, Christopher Tormey, Alexander B Pine, Alfred I Lee, Samir Gautam

{"title":"Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease.","authors":"Cecily Allen, Marina Heskel, Ayesha Butt, Christopher Tormey, Alexander B Pine, Alfred I Lee, Samir Gautam","doi":"10.1159/000540239","DOIUrl":"10.1159/000540239","url":null,"abstract":"Introduction: Distinguishing disseminated intravascular coagulation (DIC) from the coagulopathy of liver disease represents a common clinical challenge. Here, we evaluated the utility of two diagnostic tools frequently used to differentiate between these conditions: factor VIII (FVIII) levels and the International Society on Thrombosis and Hemostasis (ISTH) DIC score.Methods: To this end, we conducted a retrospective chart review of patients with DIC, liver disease, or both. Multiple logistic regression was performed, and receiver operating characteristic curves were generated to calculate the area under curve (AUC) for distinguishing DIC in the setting of liver disease.Results: Among 123 patients with DIC, liver disease, or liver disease plus DIC, FVIII levels did not differ significantly. ISTH scores were lower in patients with DIC than in liver disease with or without DIC. Addition of several laboratory parameters to the ISTH score, including mean platelet volume, FV, FVIII, international normalized ratio, and activated partial thromboplastin time, improved AUC for distinguishing DIC in liver disease from liver disease alone (AUC = 0.76; p < 0.0001).Conclusion: We conclude that FVIII levels do not distinguish DIC from liver disease, and ISTH DIC scores are not predictive of DIC in patients with liver disease. Inclusion of additional lab variables within the ISTH DIC score may aid in identifying DIC in patients with liver disease.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"220-225"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0